Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Angewandte Chemie (International Ed. in English)|May 2, 2018
Carbohydrates as Multifunctional Chiral Scaffolds in Combinatorial SynthesisTobias Wunberg, Christopher Kallus, Till Opatz, et al.Carbohydrate Research|November 16, 2002
D-glucose as a multivalent chiral scaffold for combinatorial chemistryTill Opatz, Christopher Kallus, Tobias Wunberg, et al.Drug Discovery Today|March 15, 2006
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hitsTobias Wunberg, Martin Hendrix, Alexander Hillisch, et al.Archiv Der Pharmazie|February 24, 2024
Ligandability assessment of the C-terminal Rel-homology domain of NFAT1Jark Böttcher, Julian E Fuchs, Moriz Mayer, et al.Antimicrobial Agents and Chemotherapy|January 6, 2010
In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246Peter Lischka, Guy Hewlett, Tobias Wunberg, et al.Chemmedchem|September 23, 2006
In silico ADMET traffic lights as a tool for the prioritization of HTS hitsMario Lobell, Martin Hendrix, Berthold Hinzen, et al.Journal of Medicinal Chemistry|October 25, 2016
Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 InteractionAndreas Gollner, Dorothea Rudolph, Heribert Arnhof, et al.Nature|May 31, 2023
Pan-KRAS inhibitor disables oncogenic signalling and tumour growthDongsung Kim, Lorenz Herdeis, Dorothea Rudolph, et al.Journal of Medicinal Chemistry|August 27, 2025
Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft ModelJames C Tarr, Kyuok Jeon, Nagarathanam Veerasamy, et al.Journal of Medicinal Chemistry|October 27, 2022
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C InhibitorJoachim Bröker, Alex G Waterson, Chris Smethurst, et al.Pageof 2